DUBLIN--(BUSINESS WIRE)--The "LUMIGAN Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
LUMIGAN Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on LUMIGAN and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- FDA Paragraph IV patent challenges
- District Court patent litigation
- European supplementatry protection certificates (SPCs)
- Clinical trials
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Topics Covered
- Profile for LUMIGAN
- US Patents
- Expired US Patents
- Paragraph IV Patent Challenges
- US District Court Litigation
- International (ex US) Patents
- Supplementary Protection Certificates
- Clinical Trials
- Drug Prices - Average Pharmacy Cost
- Drug Prices - Best Wholesale Price
- Annual Sales Revenues
- Finished Product Suppliers
- Bulk API Sources
Companies Featured
- Allergan Inc.
- Ispharm
- Abi Chem
- Chemmol
- Akos Consulting & Solutions
- Active Biopharma
- Wutech
- Apexmol
- Abachemscene
- An Pharmatech
- Irvine Chemistry Lab
- Avachem Scientific
- Race Chemical
- Molepedia
- Ark Pharm Inc.
- Targetmol
- Boc Sciences
- Parchem
- Ichemical Technology USA Inc
- Chem-Space.com Database
- Enovation Chemicals
- Abovchem Llc
- Acorn Pharmatech
- Sigma-Aldrich
- Achemo Scientific Limited
- Pi Chemicals
- LGC Standards
- Ochem
- Molport
- Musechem
- Combi-Blocks
- Bld Pharm
- Ambeed
-
and many more...
For more information about this report visit https://www.researchandmarkets.com/research/l4r7xn/lumigan_drug?w=4
